These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 39124882)
1. Molecular Hybrid Design, Synthesis, In Vitro Cytotoxicity, In Silico ADME and Molecular Docking Studies of New Benzoate Ester-Linked Arylsulfonyl Hydrazones. Ergan E; Çakmak R; Başaran E; Mali SN; Akkoc S; Annadurai S Molecules; 2024 Jul; 29(15):. PubMed ID: 39124882 [TBL] [Abstract][Full Text] [Related]
2. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities, Alam MS; Lee DU Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310 [TBL] [Abstract][Full Text] [Related]
3. 1H-benzimidazole-2-yl hydrazones as tubulin-targeting agents: Synthesis, structural characterization, anthelmintic activity and antiproliferative activity against MCF-7 breast carcinoma cells and molecular docking studies. Anichina K; Argirova M; Tzoneva R; Uzunova V; Mavrova A; Vuchev D; Popova-Daskalova G; Fratev F; Guncheva M; Yancheva D Chem Biol Interact; 2021 Aug; 345():109540. PubMed ID: 34139148 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, Anti-Proliferative, Anti-microbial, Anti-Angiogenic Activity and Ünver H; Berber B; Demirel R; Koparal AT Anticancer Agents Med Chem; 2019; 19(13):1658-1669. PubMed ID: 30887930 [TBL] [Abstract][Full Text] [Related]
5. Novel Hydrazone Derivatives of 3-Bromopyruvate: Synthesis, Evaluation of the Cytotoxic Effects, Molecular Docking and ADME Studies. Beygi F; Mostoufi A; Mojaddami A Chem Biodivers; 2022 Jun; 19(6):e202100754. PubMed ID: 35427437 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents. Alam MS; Lee DU Arch Pharm Res; 2016 Feb; 39(2):191-201. PubMed ID: 26694484 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Characterization of New Series of 1,3-5-Triazine Hydrazone Derivatives with Promising Antiproliferative Activity. H Al Rasheed HHA; M Malebari AM; A Dahlous KA; El-Faham A Molecules; 2020 Jun; 25(11):. PubMed ID: 32545272 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755 [TBL] [Abstract][Full Text] [Related]
9. New Anthranilic Acid Hydrazones as Fenamate Isosteres: Synthesis, Characterization, Molecular Docking, Dynamics & in Silico ADME, in Vitro Anti-Inflammatory and Anticancer Activity Studies. Şenol H; Çağman Z; Gençoğlu Katmerlikaya T; Sinan Tokalı F Chem Biodivers; 2023 Aug; 20(8):e202300773. PubMed ID: 37384873 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors. Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
12. A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer. Orujova T; Ece A; Akalın Çiftçi G; Özdemir A; Altıntop MD Drug Dev Res; 2023 Apr; 84(2):185-199. PubMed ID: 36469421 [TBL] [Abstract][Full Text] [Related]
13. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors. Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725 [TBL] [Abstract][Full Text] [Related]
14. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties. Zebbiche Z; Tekin S; Küçükbay H; Yüksel F; Boumoud B Arch Pharm (Weinheim); 2021 May; 354(5):e2000377. PubMed ID: 33368627 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of N Zhao Z; Wang H; Tian N; Yan H; Wang J Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100213. PubMed ID: 34368988 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-naproxen. Han MI; Bekçi H; Uba AI; Yıldırım Y; Karasulu E; Cumaoğlu A; Karasulu HY; Yelekçi K; Yılmaz Ö; Küçükgüzel ŞG Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800365. PubMed ID: 31115928 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors. Şenkardeş S; Han Mİ; Kulabaş N; Abbak M; Çevik Ö; Küçükgüzel İ; Küçükgüzel ŞG Mol Divers; 2020 Aug; 24(3):673-689. PubMed ID: 31302853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]